《投资者网》蔡俊尽管内部承压不断,但石药集团(01093.HK,下称“公司”)与实控人蔡东晨的财富还在增长。近期,公司公告称正与若干独立第三方磋商三项潜在交易,涉及旗下表皮生长因子受体抗体药物偶联物(EGFR-ADC)等产品的开发、生产及商业化授权合作。每笔交易的潜在首付款、开发里程碑付款及商业化里程碑付款合计可达约50亿美元。之后,公司与阿斯利康的合作浮出水面。业绩承压之下,公司或受该利好影响,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.